- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Celltrion completes acquisition of U.S. Eli Lilly plant | 3 | Korea Herald | ||
| Fr | Celltrion Acquires Eli Lilly's U.S. Facility with 680 billion won CMO Contract | 12 | BusinessKorea | ||
| Fr | Celltrion completes acquisition of US biopharmaceutical plant | 1 | Korea Times | ||
| Fr | Celltrion completes acquisition of U.S. biopharmaceutical plant | 1 | Yonhap News | ||
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| Mi | Celltrion Seen Topping 4 Tril. Won in Annual Revenue and 1 Tril. Won in OP This Year | 1 | BusinessKorea | ||
| Mi | Celltrion projects first-ever 1 tln-won annual operating profit for 2025 | 2 | Yonhap News | ||
| Mi | Celltrion forecasts 137% year-on-year growth in 2025 profits | 1 | Korea Times | ||
| 29.12.25 | Dividendenbekanntmachungen (29.12.2025) | 11.528 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADWAYS INC JP3121970002 6,35 JPY 0,0344 EUR AGC INC JP3112000009 105 JPY 0,5701 EUR AMERICAN TOWER CORPORATION US03027X1000 1... ► Artikel lesen | |
| 22.12.25 | Celltrion launches biosimilar Stoboclo-Osenvelt in Europe | 1 | Yonhap News | ||
| 18.12.25 | Celltrion receives positive CHMP Opinion for SteQeyma (ustekinumab biosimilar) autoinjector | 1 | City A.M. | ||
| 18.12.25 | Celltrion, Inc.: Celltrion erhält positive CHMP-Stellungnahme für den SteQeyma (Ustekinumab-Biosimilar) Fertigpen | 395 | Business Wire | SteQeyma 45 mg und 90 mg Injektionslösung in einem Fertigpen erhält positive CHMP-Stellungnahme, die die subkutane Verabreichung bei Patienten mit Plaque-Psoriasis, Psoriasis-Arthritis (PsA)... ► Artikel lesen | |
| 18.12.25 | Celltrion, Inc.: Celltrion receives positive CHMP Opinion for SteQeyma (ustekinumab biosimilar) autoinjector | 433 | Business Wire | SteQeyma45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis... ► Artikel lesen | |
| 14.12.25 | Celltrion's Remsima stays Korea's top-produced drug | 2 | Korea Herald | ||
| 12.12.25 | Celltrion's Abtozma Gains Major U.S. PBM Listing | 2 | BusinessKorea | ||
| 12.12.25 | Celltrion's Avtozma biosimilar added to U.S. preferred drug list | 2 | Yonhap News | ||
| 09.12.25 | Celltrion Enters SC Formulation Market | 1 | BusinessKorea | ||
| 04.12.25 | Celltrion ADC candidate gets FDA fast track designation | 4 | Korea Herald | ||
| 03.12.25 | FDA Clears New Prefilled Syringe Of Celltrion's OMLYCLO, Interchangeable Biosimilar To XOLAIR | 379 | AFX News | SEOUL (dpa-AFX) - Celltrion Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO (omalizumab-igec)-the first and only biosimilar designated... ► Artikel lesen | |
| 03.12.25 | FDA approves new dosing option for Celltrion's omalizumab biosimilar | 13 | Investing.com | ||
| 03.12.25 | Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR | 136 | PR Newswire | FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports... ► Artikel lesen |
1 2 3 4 5 Weiter >>
122 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PROTAGONIST THERAPEUTICS | 87,18 | -0,18 % | Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,740 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 286,40 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor | The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,09 | -0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 72,76 | -6,49 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,000 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,880 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,500 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 75,78 | 0,00 % | BTIG bestätigt Kaufempfehlung für Apogee Therapeutics angesichts positiver Aussichten | ||
| NUVALENT | 100,84 | +0,25 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,200 | 0,00 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| IMMUNOME | 20,820 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ARS PHARMACEUTICALS | 11,490 | -1,37 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,140 | 0,00 % | Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? | ||
| NURIX THERAPEUTICS | 18,060 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen |
CELLTRION INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.